Compare BioNTech SE - ADR (BNTX) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Main Street Capital Corporation — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Main Street Capital Corporation trades at $53.2 (market cap $4.94B). The key difference: BioNTech SE - ADR is far larger — about 4.6× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 8.25% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MAIN | |
|---|---|---|
Market Cap | $22.86B | $4.94B |
Sector | Health | Financials |
52-Week High | $119.34 | $67.54 |
52-Week Low | $83.89 | $49.63 |
Enterprise Value | $6.53B | — |
Dividend Yield | — | 8.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Main Street Capital (MAIN) trades at $52.51, down 0.62% on the day, with a bullish technical signal from moving averages. The company reported a net income margin of 81.08% for 2025, though revenue dipped to $592M from $601M in 2024. Recent news highlights MAIN's premium valuation among internally managed BDCs and a consistent dividend history, with the latest quarterly earnings showing a mix of beats and misses against expectations.
The outlook is supported by a consensus price target of $57.75, implying upside, but risks include softening earnings and negative operating cash flow. The stock offers a high yield, but investors should weigh the sustainability of dividends against rising expenses and a higher share count noted in recent analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
